Abstract
The incretin hormone glucagon like peptide-1 (GLP-1) has insulinotropic actions that contribute to the maintenance of the blood glucose levels, and it is therefore considered a potential target for the treatment of type 2 Diabetes (DM2). In an attempt to overcome the limitations to the therapeutic use of GLP-1, the following strategies have been employed: (i) the use of incretin mimetics …